Filing Flows › NextPlat (NXPL) › Q1 2026 › vs Q1 2025
NextPlat (NXPL) Q1 2026 vs Q1 2025 (year over year)
NextPlat's revenue fell $4.1M (-29%) from $13.9M in Q1 2025 to $9.9M in Q1 2026. The biggest changes: Pharmacy Prescription and Other Revenue, Net of PBM Fees −$4.7M (-50%); Pharmacy Contract Revenue +$443K (+31%); E-Commerce Revenue +$193K (+6%).
NextPlat, Q1 2026: revenue $9.9M (-29% year over year), operating margin -11.2%, net loss $1.1M, operating cash flow −$2.6M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Pharmacy Prescription and Other Revenue, Net of PBM Fees | $4.8M | $9.5M | −$4.7M | -50% |
| E-Commerce Revenue | $3.2M | $3.0M | $193K | +6% |
| Pharmacy Contract Revenue | $1.9M | $1.4M | $443K | +31% |
| Revenue | $9.9M | $13.9M | −$4.1M | -29% |
| Net loss | $1.1M | $1.9M | −$810K | -42% |
| Costs & expenses | $11.0M | $16.0M | −$5.0M | -31% |
| Operating costs | $11.0M | $16.0M | −$5.1M | -32% |
| Cost of revenue | $6.4M | $11.1M | −$4.6M | -42% |
| SG&A | $2.0M | $2.0M | −$31K | -2% |
| Other operating costs | $2.5M | $2.9M | −$402K | -14% |
| Operating cash sources | $3.0M | $9.2M | −$6.3M | -68% |
| Depreciation & amortization | $90K | $191K | −$101K | -53% |
| Share-based compensation | $300K | $7.0M | −$6.7M | -96% |
| Cash used in operations | $2.6M | $2.1M | $524K | +25% |
| Net loss absorbed | $1.1M | $1.9M | −$810K | -42% |
| Working capital & other | $1.8M | $7.3M | −$5.5M | -75% |
Questions
How much did NextPlat's revenue grow year over year in Q1 2026?
NextPlat's revenue fell $4.1M (-29%) from $13.9M in Q1 2025 to $9.9M in Q1 2026.
What drove NextPlat's revenue change in Q1 2026?
Pharmacy Prescription and Other Revenue, Net of PBM Fees −$4.7M (-50%); Pharmacy Contract Revenue +$443K (+31%); E-Commerce Revenue +$193K (+6%).